Market Research Logo

Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)

Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period of time and varies according to the type of causing factor and according to the age group of the person. The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or addiction, low-stress tolerance level, mood swings and many more. Further, on the basis of symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient mental and behavior condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies and EEG biofeedback therapies, physicians could reduce the disorder symptoms and its effects on the individual health.

The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy.

The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs and mounting occurrence of ADHD. Key trends and developments of this market includes progressing drugs under pipeline, high demand for dual therapy and rising preference for EEG biofeedback therapy. However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.

The report “Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Shire Plc, Johnson and Johnson, Eli Lilly and Company and Novartis International AG.


1. ADHD Overview
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Classification
Table 1: Categories of ADHD by Symptoms
1.5 Diagnosis
1.6 Treatment
2. Global ADHD Market
2.1 Global ADHD Market Value Forecast
Table 2: Global ADHD Market Value Forecast (2017-2022)
2.2 Global ADHD Market Value by Region
Table 3: Global ADHD Market Value by Region (2017)
2.3 Global ADHD Patient Population Forecast
Table 4: Global ADHD Patient Population Forecast (2017-2022)
3. Regional ADHD Market
3.1 The U.S.
3.1.1 The U.S. ADHD Market Value
Table 5: The U.S. ADHD Market Value (2013-2017)
3.1.2 The U.S. ADHD Market Value Forecast
Table 6: The U.S. ADHD Market Value Forecast (2018-2022)
3.1.3 The U.S. ADHD Market Revenue by Drugs
Table 7: The U.S. ADHD Market Revenue by Drugs* (2017)
3.1.4 The U.S. Vyvanse Drug Revenue Forecast
Table 8: The U.S. Vyvanse Drug Revenue Forecast (2017-2022)
3.1.5 The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast
Table 9: The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast (2017-2022)
3.1.6 The U.S. Adderall XR Drug Revenue Forecast
Table 10: The U.S. Adderall XR Drug Revenue Forecast (2017-2022)
3.1.7 The U.S. ADHD Drugs Revenue by Categories
Table 11: The U.S. ADHD Drugs Revenue by Categories (2017)
3.1.8 The U.S. ADHD Adult Patient Population Forecast
Table 12: The U.S. ADHD Adult Patient Population Forecast (2017-2022)
3.1.9 The U.S. ADHD Total Prescriptions
Table 13: The U.S. ADHD Total Prescriptions (2013-2017)
3.1.10 The U.S. ADHD Total Prescriptions Forecast
Table 14: The U.S. ADHD Total Prescriptions Forecast (2018-2022)
3.1.11 The U.S. ADHD Total Prescriptions by Drugs
Table 15: The U.S. ADHD Total Prescriptions by Drugs (2017)
3.1.12 The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast
Table 16: The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast (2017-2022)
3.1.13 The U.S. Vyvanse Total Prescriptions Forecast
Table 17: The U.S. Vyvanse Total Prescriptions Forecast (2017-2022)
3.1.14 The U.S. Concerta Total Prescriptions Forecast
Table 18: The U.S. Concerta Total Prescriptions Forecast (2017-2022)
3.2 Europe
3.2.1 Europe ADHD Market Value Forecast
Table 19: Europe ADHD Market Value Forecast (2017-2022)
3.2.2 Europe ADHD Patient Population Forecast
Table 20: Europe ADHD Patient Population Forecast (2017-2022)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Pharmaceutical R&D Spending
Table 21: Global Pharmaceutical R&D Spending (2013-2017)
4.1.2 Growing Healthcare Expenditure
Table 22: Global Healthcare Expenditure (2013-2017)
4.1.3 Accelerating Economic Growth
Table 23: Global GDP Per Capita (2013-2017)
4.1.4 Unmet Treatment Needs
4.1.5 Mounting Occurrence of ADHD
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
Table 24: Drugs under Development for ADHD (2018)
4.2.2 High Demand for Dual Therapy
4.2.3 Rising Preference for EEG Biofeedback Therapy
4.3 Challenges
4.3.1 Medical Complications of Existing Drug Therapies
Table 25: Medical Complications of Existing Drug Therapies
4.3.2 High Domination of Generic Pharmaceutical Market
Table 26: Generic vs. Patented Drugs Price Comparison (2018)
4.3.3 Strict Government Protocols
5. Competitive Landscape
5.1 Global ADHD Market
5.1.1 Key Players – Revenues Comparison
Table 27: Key Players – Revenues Comparison (2017)
5.1.2 Key Players - Market Cap Comparison
Table 28: Key Players - Market Cap Comparison (2018*)
5.1.3 Key Players – ADHD Prescription Cost Comparison
Table 29: Key Players – ADHD Prescription Cost Comparison (2018)
6. Company Profiles
6.1 Shire Plc
6.1.1 Business Overview
Table 30: Shire Net Revenues by Therapeutic Areas (2017)
6.1.2 Financial Overview
Table 31: Shire Net Revenues and Net Income (2013-2017)
6.1.3 Business Strategies
Table 32: Shire R&D Expenditures (2015-2017)
Table 33: Shire A&P Expenditures (2015-2017)
6.2 Johnson and Johnson
6.2.1 Business Overview
Table 34: J&J Net Sales by Business Segments (2017)
6.2.2 Financial Overview
Table 35: J&J Net Sales and Net Earnings (2013-2017)
6.2.3 Business Strategies
Table 36: J&J R&D Expenditures (2015-2017)
Table 37: J&J Significant Agreements (2018/2017)
6.3 Eli Lilly and Company
6.3.1 Business Overview
Table 38: Eli Lilly Revenues by Business Segments (2017)
6.3.2 Financial Overview
Table 39: Eli Lilly Revenues and Net Income (Loss) (2013-2017)
6.3.3 Business Strategies
Table 40: Eli Lilly A&P Expenditures (2015-2017)
6.4 Novartis International AG
6.4.1 Business Overview
Table 41: Novartis Net Sales by Business Segments (2017)
6.4.2 Financial Overview
Table 42: Novartis Net Sales and Net Income (2013-2017)
6.4.3 Business Strategies
Table 43: Novartis R&D Expenditures (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report